Skip to content
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Jezik
Vsa polja
Naslov
Avtor
Tema
Signatura
ISBN/ISSN
Oznaka
Išči
Napredno
Inability to Tolerate Standard...
Citiraj
Pošljite SMS
Pošljite email
Natisni
Izvozi zadetek
Izvozi v RefWorks
Izvozi v EndNoteWeb
Izvozi v EndNote
Permanent link
Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL) Results From the International MRC/ECOG Trial
Show other versions (2)
Bibliografske podrobnosti
Main Authors:
Sive, J
,
Buck, G
,
Fielding, A
,
Lazarus, H
,
Litzow, MR
,
Luger, S
,
Marks, D
,
McMillan, A
,
Richards, S
,
Rowe, J
,
Tallman, MS
,
Goldstone, A
Format:
Conference item
Izdano:
2010
Zaloga
Opis
Other Versions (2)
Podobne knjige/članki
Knjižničarski pogled
Opis
Izvleček:
Podobne knjige/članki
Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL) Results From the International MRC/ECOG Trial
od: Sive, J, et al.
Izdano: (2010)
Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL): Results From the International MRC/ECOG Trial
od: Sive, J, et al.
Izdano: (2010)
Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial.
od: Sive, J, et al.
Izdano: (2012)
Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study.
od: Fielding, A, et al.
Izdano: (2007)
Imatinib Significantly Enhances Long-Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia; Final Results of the UKALLXII/ECOG2993 Trial
od: Fielding, A, et al.
Izdano: (2010)